Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 18/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 11/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22132822 | 1.00 | FGFR1 (0.64) | FGFR1FGFR3FGFR4FGFR2KDR | |
| SCHEMBL22132920 | 1.00 | FGFR1 (0.64) | FGFR1FGFR3FGFR4FGFR2KDR | |
| SCHEMBL22186196 | 0.89 | FGFR1 (0.62) | FGFR1FGFR3FGFR4 | |
| SCHEMBL22132777 | 0.89 | FGFR1 (0.62) | FGFR1FGFR3FGFR4 | |
| SCHEMBL22186197 | 0.89 | FGFR1 (0.62) | FGFR1FGFR3FGFR4 | |
| SCHEMBL22132836 | 0.88 | FGFR1 (0.61) | FGFR1FGFR3FGFR4 | |
| SCHEMBL27188430 | 0.86 | FGFR4 (0.66) | FGFR1FGFR3FGFR4FGFR2KDR | |
| SCHEMBL27188422 | 0.86 | FGFR4 (0.66) | FGFR1FGFR3FGFR4FGFR2KDR | |
| SCHEMBL22132921 | 0.83 | FGFR1 (0.63) | FGFR1FGFR3FGFR4FGFR2KDR | |
| SCHEMBL22132910 | 0.83 | FGFR1 (0.63) | FGFR1FGFR3FGFR4FGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3670513-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | FGFR1 1/4885FGFR3 4/4885FGFR4 3/4885 |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR3 3/4885FGFR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.